Bristol-Myers Squibb Company BMY
62.93 USD -0.50 (-0.79%)
Regular-session close
62.68 -0.25 -0.40%
Pre-market · Nov 17, 5:52 AM ET
62.82 Day range 64.94
45.27 52-week range 68.64
- YTD
- +16.67%
- 1 year
- +34.90%
News
fool.com 5 Dividend Stocks With High Yields That Are Safer Than You Might Think A high yield is a sign that investors are worried about a business, but sometimes that concern is overwrought.
fool.com Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story. Bristol Myers Squibb is a large and well-respected drug maker. The company is facing the normal industry headwind of patent expirations.
defenseworld.net Bristol Myers Squibb Company $BMY Stock: Allworth Financial LP Raises Stake Allworth Financial LP lifted its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 71.3% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The…
247wallst.com 4 Healthcare Dividend Stocks for Retirees. One Yields Over 4% A fat starting yield can hide thin raises, while the slowest payers boast decades of increases. Four low-volatility healthcare blue chips force retirees to choose between income today and income that…
zacks.com Can BMY Sustain Growth in Its Cardiovascular Franchise? Bristol Myers Squibb is expanding Camzyos??? reach, benefiting from Eliquis?
marketwatch.com 14 dividend stocks selected for long-term growth There are a variety of ways to select dividend stocks. John Buckingham, a veteran value-oriented stock picker, believes the best approach is to focus on a stock's total return potential, which means…
247wallst.com How to Use the Years Between 62 and 75 to Turn a $1.05 Million IRA Into $5,100 a Month Tax-Free When the paychecks stop at 62 and Social Security can wait, a short stretch of near-zero income opens a tax window most retirees never notice. Miss it, and the IRS decides how much you withdraw at 75.
247wallst.com A Record-High Dividend Yield Can Be a Warning Sign. Just Ask Pfizer A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.
reuters.com Bristol Myers to merge scientific, clinical teams under new R&D structure Bristol Myers to merge scientific, clinical teams under new R&D structurebenzinga.com Bristol Myers Squibb Appoints Cristian Massacesi To Lead A Unified, End-To-End R&D Organization, Effective January 1, 2027 As part of this planned transition, Robert Plenge will remain with Bristol Myers Squibb in an advisory capacity through March 2027 to support a seamless transition before departing the…
businesswire.com Bristol Myers Squibb Announces Evolution of Research & Development Organization PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--Bristol Myers Squibb Announces Evolution of Research & Development Organization.
barrons.com Our Bristol Myers Squibb Stock Pick Is Up 35%. It's Still a Good Bet in Healthcare. The stock is still attractive trading at 10 times forward earnings.
247wallst.com Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year Every one of these drugmakers is staring down a patent cliff, and that looming drop in sales is exactly why their dividends pay what they do. Which one carries the most risk, and which one rewards…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.
247wallst.com $200,000 in Dividend Stocks: How a Roth IRA Could Save You $2,166 a Year Six famous high-yield stocks pay the same income wherever you hold them, yet two of them quietly trigger most of the tax bill. Find out which two, and why the account you choose matters more than the…
defenseworld.net Bristol Myers Squibb Company $BMY Holdings Trimmed by AEGON ASSET MANAGEMENT UK Plc AEGON ASSET MANAGEMENT UK Plc trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 6.3% during the undefined quarter, according to its most recent disclosure with the…
benzinga.com Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.benzinga.com Bristol Myers Squibb Presents 56-Week Results From Phase 3 SCOUT-HCM Clinical Trial In Late-Breaker Presentation At HCMS Scientific Sessions With a consistent efficacy and safety profile through 56-weeks of follow-up, the Phase 3 SCOUT-HCM clinical trial further reinforces Camzyos as the first approved treatment for pediatric patients ≥30…
benzinga.com Tempus AI Says It Is Uniquely Positioned Tempus AI stock rises after beating Q3 earnings estimates and securing $192.5 million in data deals with Bristol Myers Squibb and Pathos.benzinga.com Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40 Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.
benzinga.com Bristol-Myers Squibb Says AI Is Already Speeding Up Drug Research — And It's Measuring The Impact Bristol-Myers beats Q3 2026 estimates with $13.07B in revenue and raises full-year sales guidance driven by newer drug growth.
benzinga.com Bristol-Myers Squibb Q3 2026 Earnings Call Transcript Bristol-Myers Squibb (NYSE:BMY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Bristol-Myers Squibb Lowers FY2026 Adj EPS Guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 Est; Raises FY2026 Sales Guidance from $49.000B-$50.000B to $49.750B-$50.250B vs $49.886B Est Bristol-Myers Squibb (NYSE:BMY) lowers FY2026 Adj EPS guidance from $6.75-$7.00 to $6.35-$6.55 vs $6.54 analyst estimate. Raises FY2026 sales outlook from $49.000 billion-$50.000 billion to $49.750…
benzinga.com Bristol-Myers Squibb Q3 Adj. EPS $1.35 Beats $1.17 Estimate, Sales $13.069B Beat $12.738B Estimate Bristol-Myers Squibb (NYSE:BMY) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.17 by 15.38 percent. This is a 17.18 percent decrease over earnings of…
benzinga.com Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings Amazon, Intel, Sandisk and six other stocks report earnings Thursday. See implied moves, analyst estimates and the billions in market value at stake.
benzinga.com Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…benzinga.com Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78 Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.
benzinga.com Bristol Myers Squibb, SystImmune’s Iza-Bren Hits Primary Endpoint In Phase 3 PANKU-Lung01 Interim Analysis, Median PFS 11.1 Versus 5.7 Months (HR 0.40) Over Platinum Chemotherapy In EGFR-Mutated NSCLC Late-breaking results to be presented in an oral presentation at ESMO 2026PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this…
benzinga.com What's Going On with Bristol Myers Squibb Stock on Friday? Bristol Myers Squibb releases trial results for their multiple sclerosis CAR T therapy and Phase 3 breast cancer conjugate candidate.benzinga.com Bristol Myers Squibb Presents Interim Safety, Efficacy Data From Its Multiple Sclerosis Groups Of Phase 1 Trial Of Zolacabtagene Autoleucel At MSToronto 2026 Bristol Myers Squibb (NYSE:BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2…
benzinga.com Tempus AI Enters Multiyear Agreement With Bristol Myers Squibb For BMY To License Multimodal Oncology Data Through 2031 To Support Biological And Clinical Insight Identification, Novel Drug Target Discovery And Therapeutic Development Across Its Oncology Portfolio Additionally, BMS will gain access to Tempus’ Lens Platform, an AI-first, agentic platform for oncology drug development built on one of the world’s largest, real-world multimodal datasets. Connected…
benzinga.com SystImmune And Bristol Myers Report Phase 3 PANKU-Breast01 Interim Analysis Shows Izalontamab Brengitecan Cuts Progression Or Death Risk By 59% Vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer; Results To Be Presented At ESMO 2026 Late-breaking results to be presented in an oral presentation at ESMO 2026With two positive Phase 3 trials in breast cancer, these data reinforce the potential of iza-bren to further redefine…
benzinga.com BioNTech To Present New Clinical Data From Its Late-Stage Oncology Pipeline With 16 Abstracts At European Society For Medical Oncology, October 23–27; Key Oral Presentations Will Focus On Clinical Data For Pumitamig Plus Docetaxel In Second-Line Metastatic Non-Small Cell Lung Cancer Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in…
ainvest.com Humankind Exits Microsoft, Apple, and Cisco Humankind Investments fully exited Microsoft, Apple, and Cisco in Q3 2026, removing 21% of its prior portfolio value.
finance.yahoo.com Mayne Pharma shares surge on $407 mln takeover offer from Gedeon Richter Investing.com-- Australian pharmaceutical company Mayne Pharma (ASX:MYX) said on Tuesday it had agreed to be acquired by ...
twelfthmagpie.com 2 passive income shares with 22+ years of dividend growth! These FTSE 100 and FTSE 250 passive income shares have been growing dividends for decades. Royston Wild explains why this looks set to continue. You’re reading a free article with opinions that may…
finance.yahoo.com Mayne Pharma shareholders set for windfall as Gedeon Richter launches $604 million takeover Mayne Pharma Group Ltd (ASX:MYX, OTC:MAYNF) shareholders are set for a substantial windfall after 125-year-old Hungarian ...
seekingalpha.com White House getting antsy over FDA commissioner nominee Heidi Overton Trump officials consider dropping Heidi Overton's FDA nomination over doubts she can win Senate confirmation. Read more here.
reuters.com Summit shares drop after US FDA declines to approve lung cancer drug Shares of Summit Therapeutics fell nearly 20% in premarket trading on Monday after the US Food and Drug Administration ...
ad-hoc-news.de Bristol Myers Squibb stock: Zacks lifts 2027 EPS estimate Zacks Research raised its third-quarter 2027 EPS estimate to 1.74 US dollars from 1.55. Bristol Myers Squibb stock remains ...
seekingalpha.com Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy Travere Therapeutics has achieved two significant FDA approvals for FILSPARI, driving notable revenue growth. See why I rate ...
msn.com Summit crumbles after FDA rejects Merck-rivaling lung cancer drug Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug, ivonescimab.
theglobeandmail.com Barclays Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY) Detailed price information for Bristol-Myers Squibb (BMY-N) from The Globe and Mail including charting and trades.
